开放期刊系统

三阴型乳腺癌治疗策略的最新进展

倪 春晓, 徐加 菊*, 张 玲

摘要

三阴性乳腺癌 (triple-negative breast cancer, TNBC) 作为一种具有生物活性的乳腺癌,常在晚期才被发现,易转移,
复发频繁,且在复发后死亡率高,预后差。虽然化疗是 TNBC 患者的主要治疗方式,但疗效仍然有限。因此,及时开发新
的治疗方法和靶点至关重要,且迫在眉睫。根据 TNBC 中表达的特定分子和信号通路,目前已出现了多种靶向治疗策略。
此外,免疫检查点抑制剂和抗体 - 药物偶联物也在临床中被广泛探索。

关键词

TNBC;VEGFR;PARP;ICIs;ADC;TROP2;治疗

全文:

PDF

参考

[1]Mohamed RF, Bakri HM, Abdelfattah ON, Eid S. Does

bevacizumab carry a hope for metastatic triple-negative breast

cancer in the era of immunotherapy? Anticancer Drugs 2022;

33:e604-e609.

[2]Bahhnassy A, Mohanad M, Shaarawy S, et al. Transforming

growth factor-beta, insulin-like growth factor I/insulin-like

growth factor I receptor and vascular endothelial growth factor-A:

prognostic and predictive markers in triple-negative and non-

triple-negative breast cancer. Mol Med Rep 2015; 12:851-64.

[3]Hamilton E, Kimmick G, Hopkins J, et al. Nab-paclitaxel/

bevacizumab/carboplatin chemotherapy in first-line triple negative

metastatic breast cancer. Clin Breast Cancer 2013; 13:416-20.

[4]GerberB,LoiblS,EidtmannH,et al. Neoadjuvant

bevacizumab and anthracycline-taxane-based chemotherapy

in 678 triple-negative primary breast cancers; results from the

geparquinto study (GBG 44). Ann Oncol 2013; 24:2978-84.

[5]van Rossum AGJ, Mandjes IAM, van Werkhoven E, et

al. Carboplatin-Cyclophosphamide or Paclitaxel without or with

Bevacizumab as First-Line Treatment for Metastatic Triple-

Negative Breast Cancer (BOOG 2013-01). Breast Care (Basel)

2021; 16:598-606.

[6]Yang JZ, Bao YF, Ci YJ, Zhu JJ. Efficacy of neoadjuvant

chemotherapy combined with low-dose Apatinib in the treatment

of triple negative breast cancer. Asian J Surg 2023; 46:2703-

2704.

[7]Fan W, Ding J, Zhong W. Efficacy and Safety of Third-

Line Apatinib plus Chemotherapy in Metastatic Triple-Negative

Breast Cancer Patients: A Multicenter, Retrospective, Cohort

Study. Tohoku J Exp Med 2023; 260:13-20.

[8]Liu J, He M, Ou K, et al. Efficacy and safety of apatinib

combined with dose-dense paclitaxel and carboplatin in

neoadjuvant therapy for locally advanced triple-negative breast

cancer: A prospective cohort study with propensity-matched

analysis. Int J Cancer 2024; 154:133-144.

[9]Huang W, Wang C, Shen Y, et al. A real-world study

of the effectiveness and safety of apatinib-based regimens in

metastatic triple-negative breast cancer. BMC Cancer 2024;

24:39.

[10]Yi M, Dong B, Qin S, et al. Advances and perspectives of

PARP inhibitors. Exp Hematol Oncol 2019; 8:29.

[11]Zhu S, Wu Y, Song B, et al. Recent advances in targeted

strategies for triple-negative breast cancer. J Hematol Oncol 2023;

16:100.

[12] 胡洋 , 张清媛 . PARP 抑制剂治疗 BRCA1/2 突变转

移性乳腺癌的研究进展 . 实用肿瘤学杂志 2021; 35:184-187.

[13]Robson ME, Im SA, Senkus E, et al. OlympiAD extended

follow-up for overall survival and safety: Olaparib versus

chemotherapy treatment of physician’s choice in patients with a

germline BRCA mutation and HER2-negative metastatic breast

cancer. Eur J Cancer 2023; 184:39-47.

[14]Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant

Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast

Cancer. N Engl J Med 2021; 384:2394-2405.

[15]Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients

with Advanced Breast Cancer and a Germline BRCA Mutation. N

Engl J Med 2018; 379:753-763.

[16]Lee KH, Sohn J, Goodwin A, et al. Talazoparib Versus

Chemotherapy in Patients with HER2-negative Advanced

Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in

Asian Countries: Exploratory Subgroup Analysis of the Phase III

EMBRACA Trial. Cancer Res Treat 2021; 53:1084-1095.

[17]Litton JK, Scoggins ME, Hess KR, et al. Neoadjuvant

Talazoparib for Patients With Operable Breast Cancer With a

Germline BRCA Pathogenic Variant. J Clin Oncol 2020; 38:388-

394.

[18]Agostinetto E, Losurdo A, Nader-Marta G, et al. Progress

and pitfalls in the use of immunotherapy for patients with triple

negative breast cancer. Expert Opin Investig Drugs 2022; 31:567-

591.

[19] 李萍 , 朱程君 , 孙月 , et al. 三阴性乳腺癌含免疫检

查点抑制剂治疗方案的Ⅲ期临床研究解析 . 中国临床研究

2022; 35:1205-1210.

[20]Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in

Patients With Advanced Triple-Negative Breast Cancer: Phase Ib

KEYNOTE-012 Study. J Clin Oncol 2016; 34:2460-7.

[21]Adams S, Schmid P, Rugo HS, et al. Pembrolizumab

monotherapy for previously treated metastatic triple-negative

breast cancer: cohort A of the phase II KEYNOTE-086 study.

Ann Oncol 2019; 30:397-404.

[22]Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab

monotherapy for previously untreated, PD-L1-positive,

metastatic triple-negative breast cancer: cohort B of the phase II

KEYNOTE-086 study. Ann Oncol 2019; 30:405-411.

[23]Schmid P, Salgado R, Park YH, et al. Pembrolizumab

plus chemotherapy as neoadjuvant treatment of high-risk, earlystage triple-negative breast cancer: results from the phase 1b

open-label, multicohort KEYNOTE-173 study. Ann Oncol 2020;

31:569-581.

[24]Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab

plus chemotherapy versus placebo plus chemotherapy for

previously untreated locally recurrent inoperable or metastatic

triple-negative breast cancer (KEYNOTE-355): a randomised,

placebo-controlled, double-blind, phase 3 clinical trial. Lancet

2020; 396:1817-1828.

[25]Schmid P, Cortes J, Dent R, et al. Event-free Survival

with Pembrolizumab in Early Triple-Negative Breast Cancer. N

Engl J Med 2022; 386:556-567.

[26]Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant

atezolizumab in combination with sequential nab-paclitaxel

and anthracycline-based chemotherapy versus placebo and

chemotherapy in patients with early-stage triple-negative breast

cancer (IMpassion031): a randomised, double-blind, phase 3 trial.

Lancet 2020; 396:1090-1100.

[27]Schmid P, Rugo HS, Adams S, et al. Atezolizumab

plus nab-paclitaxel as first-line treatment for unresectable,

locally advanced or metastatic triple-negative breast cancer

(IMpassion130): updated efficacy results from a randomised,

double-blind, placebo-controlled, phase 3 trial. Lancet Oncol

2020; 21:44-59.

[28]Miles D, Gligorov J, Andre F, et al. Primary results from

IMpassion131, a double-blind, placebo-controlled, randomised

phase III trial of first-line paclitaxel with or without atezolizumab

for unresectable locally advanced/metastatic triple-negative breast

cancer. Ann Oncol 2021; 32:994-1004.

[29]Chu Y, Zhou X, Wang X. Antibody-drug conjugates for

the treatment of lymphoma: clinical advances and latest progress.

J Hematol Oncol 2021; 14:88.

[30]Qiu S, Zhang J, Wang Z, et al. Targeting Trop-2 in

cancer: Recent research progress and clinical application. Biochim

Biophys Acta Rev Cancer 2023; 1878:188902.

[31]Jeon Y, Jo U, Hong J, et al. Trophoblast cell-surface

antigen 2 (TROP2) expression in triple-negative breast cancer.

BMC Cancer 2022; 22:1014.

[32]Cortesi M, Zanoni M, Maltoni R, et al. TROP2 (trophoblast

cell-surface antigen 2): a drug target for breast cancer. Expert

Opin Ther Targets 2022; 26:593-602.

[33] 张娣 , 黎立喜 , 马飞 . 戈沙妥珠单抗在乳腺癌及其

他实体瘤中临床应用的研究进展 . 癌症 2022; 41:253-258.

[34]Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab

govitecan, a Trop-2-directed antibody-drug conjugate, for

patients with epithelial cancer: final safety and efficacy results

from the phase I/II IMMU-132-01 basket trial. Ann Oncol 2021;

32:746-756.

[35]Bardia A, Tolaney SM, Punie K, et al. Biomarker

analyses in the phase III ASCENT study of sacituzumab govitecan

versus chemotherapy in patients with metastatic triple-negative

breast cancer. Ann Oncol 2021; 32:1148-1156.

[36]Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab

Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J

Med 2021; 384:1529-1541.

[37]Okajima D, Yasuda S, Maejima T, et al. Datopotamab

Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate,

Demonstrates Potent Antitumor Activity by Efficient Drug Delivery

to Tumor Cells. Mol Cancer Ther 2021; 20:2329-2340.

[38]Shastry M, Jacob S, Rugo HS, Hamilton E. Antibodydrug conjugates targeting TROP-2: Clinical development in

metastatic breast cancer. Breast 2022; 66:169-177.


(1 摘要 Views, 1 PDF Downloads)

Refbacks

  • 当前没有refback。